157 related articles for article (PubMed ID: 18158200)
21. Design, synthesis and evaluation of novel potent angiotensin II receptor 1 antagonists.
Bao X; Zhu W; Yuan W; Zhu X; Yan Y; Tang H; Chen Z
Eur J Med Chem; 2016 Nov; 123():115-127. PubMed ID: 27474928
[TBL] [Abstract][Full Text] [Related]
22. N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation.
Zhu W; Bao X; Ren H; Da Y; Wu D; Li F; Yan Y; Wang L; Chen Z
Eur J Med Chem; 2016 Jun; 115():161-78. PubMed ID: 27017546
[TBL] [Abstract][Full Text] [Related]
23. 3D QSAR studies on substituted benzimidazole derivatives as angiotensin II-AT1 receptor antagonist.
Vyas VK; Ghate M; Chintha C; Patel P
Curr Comput Aided Drug Des; 2013 Sep; 9(3):433-45. PubMed ID: 24010938
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists.
Bali A; Bansal Y; Sugumaran M; Saggu JS; Balakumar P; Kaur G; Bansal G; Sharma A; Singh M
Bioorg Med Chem Lett; 2005 Sep; 15(17):3962-5. PubMed ID: 16039125
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, characterization and antihypertensive activity of 2-phenyl substituted benzimidazoles.
Khan MT; Razi MT; Jan SU; Mukhtiar M; Gul R; IzharUllah -; Hussain A; Hashmi AM; Ahmad MT; Shahwani NA; Rabbani I
Pak J Pharm Sci; 2018 May; 31(3(Supplementary)):1067-1074. PubMed ID: 29731445
[TBL] [Abstract][Full Text] [Related]
27. [In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].
Kusumoto K
Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):236-40. PubMed ID: 22728984
[No Abstract] [Full Text] [Related]
28. Novel paramagnetic AT1 receptor antagonists.
Tan NP; Taylor MK; Bottle SE; Wright CE; Ziogas J; White JM; Schiesser CH; Jani NV
Chem Commun (Camb); 2011 Nov; 47(44):12083-5. PubMed ID: 21963998
[TBL] [Abstract][Full Text] [Related]
29. [Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives].
Naka T
Nihon Rinsho; 1993 Jun; 51(6):1575-9. PubMed ID: 8320837
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues.
Mavromoustakos T; Moutevelis-Minakakis P; Kokotos CG; Kontogianni P; Politi A; Zoumpoulakis P; Findlay J; Cox A; Balmforth A; Zoga A; Iliodromitis E
Bioorg Med Chem; 2006 Jul; 14(13):4353-60. PubMed ID: 16546395
[TBL] [Abstract][Full Text] [Related]
31. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios V; Escobar C
Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
[TBL] [Abstract][Full Text] [Related]
32. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships.
Ries UJ; Mihm G; Narr B; Hasselbach KM; Wittneben H; Entzeroth M; van Meel JC; Wienen W; Hauel NH
J Med Chem; 1993 Dec; 36(25):4040-51. PubMed ID: 8258826
[TBL] [Abstract][Full Text] [Related]
33. Novel O-[(11)C]methylated derivatives of candesartan as angiotensin II AT(1) receptor imaging ligands: radiosynthesis and ex vivo evaluation in rats.
Hadizad T; Kirkpatrick SA; Mason S; Burns K; Beanlands RS; Dasilva JN
Bioorg Med Chem; 2009 Dec; 17(23):7971-7. PubMed ID: 19879152
[TBL] [Abstract][Full Text] [Related]
34. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
35. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
Breschi MC; Calderone V; Digiacomo M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Balsamo A
J Med Chem; 2004 Nov; 47(23):5597-600. PubMed ID: 15509155
[TBL] [Abstract][Full Text] [Related]
36. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients.
Makita S; Abiko A; Naganuma Y; Moriai Y; Nakamura M
Cardiovasc Drugs Ther; 2007 Aug; 21(4):317-8. PubMed ID: 17629779
[No Abstract] [Full Text] [Related]
37. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
38. Homology modeling, binding site identification and docking study of human angiotensin II type I (Ang II-AT1) receptor.
Vyas VK; Ghate M; Patel K; Qureshi G; Shah S
Biomed Pharmacother; 2015 Aug; 74():42-8. PubMed ID: 26349961
[TBL] [Abstract][Full Text] [Related]
39. Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients.
Cicero AF; Veronesi M; Prandin MG; Di Gregori V; Ambrosioni E; Borghi C
Fundam Clin Pharmacol; 2009 Oct; 23(5):583-8. PubMed ID: 19555395
[TBL] [Abstract][Full Text] [Related]
40. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
Breschi MC; Calderone V; Digiacomo M; Macchia M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Rossello A; Testai L; Balsamo A
J Med Chem; 2006 Apr; 49(8):2628-39. PubMed ID: 16610806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
